Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the ...

As the pioneer of cancer insurance and leading third sector ... an estimated regulatory ESR above 250%. Our combined RBC, while not finalized, we estimate to be greater than 600%.

Aflac Inc (AFL) reports steady earnings with significant sales increases in Japan and the U.S., while maintaining strong capital management and shareholder returns.

Find out about the importance of managing non-specific symptoms and download our referral guidelines for UK nations.

Q1 2025 Management View CEO Daniel Amos reported that Aflac achieved adjusted earnings per diluted share of $1.66 for Q1 2025, consistent with the first quarter of 2024. Net earnings per diluted share ...

After reviewing the totality of emerging information, including external data results, the evolving treatment landscape in metastatic breast cancer ... the market as an ESR-1 mutant-only drug ...

The erythrocyte sedimentation rate was 55 mm per hour (reference range ... inflammation, and cancer. I considered the possibility that the patient had a parapneumonic effusion, given her history ...

Although there is no adenopathy, his cachexia, temporal wasting, and scaphoid abdomen are highly worrisome with respect to cancer ... The erythrocyte sedimentation rate and complement C3 and ...

Rapid breast cancer research offers new hope, as discussed by Joyce O’Shaughnessy, MD, regarding HR+/HER2– and HER2+ disease. Research continues to evolve at a rapid pace for breast cancer, with ...

1Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas.